USCOM LIMITED — Regulatory Filings 2014

Jun 15, 2014

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

==> picture [57 x 49] intentionally omitted <==

M A R K E T A N N O U N C E M E N T

Uscom appoints new US distributor for USCOM 1A monitor

Monday 16th of June 2014: Uscom (ASX code: UCM)

Uscom Limited is pleased to announce the appointment of Unetixs Vascular Inc, Rhode Island USA, as a distributor for the USCOM 1A. Unetixs Vascular Inc is a leading US manufacturer and distributor of vascular monitoring equipment and has been appointed nonexclusive USCOM 1A distributor for the USA for a period of 3 years.

Unetixs is a fully owned subsidiary of Opto Circuits (India) Ltd. Opto is an acquisitive, vertically integrated, global medical technology manufacturer and distributor specialising in primary, acute and critical care products with an annual revenue in the order of $250m USD. Opto acquired the US Companies Criticare in 2008, and Unetixs and Cardiac Science in 2010.

Executive Chairman of Uscom, Rob Phillips said, “Unetixs is an innovative US medical device manufacturer and distributor specialising in cardiovascular assessment devices. The USCOM 1A, as well as being a standard of care in critical care medicine, has an expanding role in monitoring cardiovascular disease and hypertension and is a neat fit with the Unetixs product range. This appointment follows the expansion of Uscom into the field of blood pressure and vascular assessment with the acquisition of the BP+ central blood pressure monitoring device in June last year. Unetixs parent Company, Opto Circuits India Ltd, is a world leader in the field of medical devices for primary, acute and critical care markets with a commitment to rapid global growth and we welcome this partnership.”

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices changing the approach to diagnosis and treatment of cardiovascular diseases, including hypertension and heart failure. The two products are also integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies.

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

==> picture [57 x 49] intentionally omitted <==

M A R K E T A N N O U N C E M E N T

About Uscom

Uscom Limited is an ASX listed cardiovascular medical device company. Uscom is an innovative developer and manufacturer of premium cardiovascular devices and has two practice leading technologies in the field of cardiovascular monitoring, the USCOM 1A and the BP+. The devices are both clinically validated with FDA, CE and TGA regulatory approval, and are currently being marketed into global distribution networks.

The USCOM 1A is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anesthesia, and is the device of choice for management of adult and paediatric sepsis, and for the guidance of fluid therapy.

The Uscom BP+ is a supra systolic Central Blood Pressure monitor and replaces older and more widespread BP sub systolic Blood Pressure monitoring technology. Central Blood Pressure is becoming the new standard of care measurement in hypertension and heart failure. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in cardiology, intensive care, general practice and home care.

For more information, please visit: www.uscom.com.au

Uscom Contacts Rob Phillips Executive Chairman rob@uscom.com.au

Catherine Officer Company Secretary secretary@uscom.com.au